Business

SCYNEXIS, Inc. (SCYX) Resumes Phase III Dosing for Brexafemme After 19-Month FDA Hold

May 30, 2025 - 14:00
 0
SCYNEXIS, Inc. (SCYX) Resumes Phase III Dosing for Brexafemme After 19-Month FDA Hold
Read More

Related Posts

Atea Pharmaceuticals Issues Statement Regarding Director Nominations

Atea Pharmaceuticals Issues Statement Regarding Directo...

Mar 21, 2025  3

Argentina suspends Telecom's purchase of Telefonica unit

Argentina suspends Telecom's purchase of Telefonica unit

Mar 21, 2025  2

ZipRecruiter CTO Boris Shimanovsky sells $22,788 in stock

ZipRecruiter CTO Boris Shimanovsky sells $22,788 in stock

Mar 21, 2025  0

Airlines issue travel waivers due to London's Heathrow Airport shutdown

Airlines issue travel waivers due to London's Heathrow ...

Mar 21, 2025  0

ROSEN, SKILLED INVESTOR COUNSEL, Encourages Target Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action - TGT

ROSEN, SKILLED INVESTOR COUNSEL, Encourages Target Corp...

Mar 21, 2025  0

Coty Divests Stake in SKKN by Kim

Coty Divests Stake in SKKN by Kim

Mar 21, 2025  0